

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/009,118	12/06/2001	Hyuk-Jun Nam	0136/0K089US	8450	
759	05/13/2005		EXAMINER		
Darby & Darby 805 Third Avenue			PARKIN, JEFFREY S		
New York, NY 10022			ART UNIT	PAPER NUMBER	
,			1648	1648	

DATE MAILED: 05/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/009,118	NAM ET AL.		
Examiner	Art Unit		
Jeffrey S. Parkin, Ph.D.	1648		

	Jeπrey S. Parkin, Ph.D.	1648	
-The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence add	ress
THE REPLY FILED <u>16 March, 2005,</u> FAILS TO PLACE THIS A	PPLICATION IN CONDITION FOR	R ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Notal Request for Continued Examination (RCE) in compliant time periods:	wing replies: (1) an amendment, af otice of Appeal (with appeal fee) in	fidavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
a) The period for reply expires <u>04</u> months from the mailing da	te of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I			
Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	06.07(f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropri	ate extension fee ce action; or (2) as
2. ☐ The Notice of Appeal was filed on A brief in comp	pliance with 37 CER 41 37 must be	filed within two month	e of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed	nsion thereof (37 CFR 41.37(e)), to	o avoid dismissal of th	
AMENDMENTS			
 The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co 	nsideration and/or search (see NO	, will <u>not</u> be entered be TE below);	ecause
(b) They raise the issue of new matter (see NOTE below			
(c) ☑ They are not deemed to place the application in be appeal; and/or	•		the issues for
(d) ☐ They present additional claims without canceling a		jected claims.	
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1	16 and 41.33(a)).		
4. $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	See attached Notice of Non-Co	ompliant Amendment	(PTOL-324).
5. $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$			
 Newly proposed or amended claim(s) would be a non-allowable claim(s). 			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		ill be entered and an e	explanation of
Claim(s) objected to:			
Claim(s) rejected: <u>1-3,7,8,12-19,21 and 22</u> . Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, bubecause applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 			
The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome all rejections under appe	al and/or appellant fai	ls to provide a
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attach	ed.
11. The request for reconsideration has been considered bu See Continuation Sheet.	t does NOT place the application i	n condition for allowar	ice because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper N	No(s)	
13. Other: See Continuation Sheet.	($\frac{1}{2}$	
	•	Jeffrey S. Parkin, P Primary Examiner Art Unit: 1648	h.D.

U.S. Patent and Trademark Office

Continuation of 3. NOTE: Applicants are reminded that they cannot, as a matter of right, amend any finally rejected claims, add new claims after a final rejection (e.g., 23, 24), or reinstate previously canceled claims (see 37 CFR 1.116). The proposed amendment will require further consideration and/or searching and fails to place the application in better form for appeal. Claim 23 is deficient and fails to set forth any nexus between the measurement and identification of a putative packaging inhibitor. Claim 24 fails to distinguish over the prior art and fails to set forth any functional language (see claim 1).

Continuation of 11. does NOT place the application in condition for allowance because: Applicants' arguments are directed toward the amended subject matter, which has not been entered, and are therefore moot.

Continuation of 13. Other: Claims 1-3, 7, 8, 12-19, and 22 would be allowable if amended to correct obvious typographical/grammatical deficiencies and if submitted in a separate, timely filed amendment canceling the non-allowable claims (23, 24). For instance, claim 1 should read "the HIV nucleocapsid protein", "the HIV psi (psi symbol) sequence". Claim 2 should recite "the HIV nucleocapsid". Claim 8 should recite "the HIV psi" sequence. Claim 12 should state "A microorganism comprising ..." or something similar thereto. Claims 13 and 14 should read "the vector pJC1 expressing the HIV nucleocapsid protein" and "the HIV psi" sequence. Claim 15 should read "the vector pJC1 expressing the HIV nucleocapsid protein" and "the HIV psi" sequence. Claim 16 should read "the HIV psi" sequence. Claim 17 should state "the HIV nucleocapsid" and "the HIV psi" sequence. Claim 18 should read "A method for the identification of HIV packaging inhibitors" or "A method of screening for HIV packaging inhibitors".